EP1616182A4 - Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 - Google Patents

Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2

Info

Publication number
EP1616182A4
EP1616182A4 EP04757538A EP04757538A EP1616182A4 EP 1616182 A4 EP1616182 A4 EP 1616182A4 EP 04757538 A EP04757538 A EP 04757538A EP 04757538 A EP04757538 A EP 04757538A EP 1616182 A4 EP1616182 A4 EP 1616182A4
Authority
EP
European Patent Office
Prior art keywords
beta
type
replacement therapy
hydroxysteroid dehydrogenase
enzyme replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04757538A
Other languages
German (de)
French (fr)
Other versions
EP1616182A2 (en
Inventor
Michel Gensini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc filed Critical Ethicon Inc
Publication of EP1616182A2 publication Critical patent/EP1616182A2/en
Publication of EP1616182A4 publication Critical patent/EP1616182A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
EP04757538A 2003-03-18 2004-03-17 Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 Withdrawn EP1616182A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45545703P 2003-03-18 2003-03-18
PCT/US2004/008083 WO2004082627A2 (en) 2003-03-18 2004-03-17 ENZYME REPLACEMENT THERAPY WITH 17-β-HYDROXYSTEROID DEHYDROGENASE-TYPE 2

Publications (2)

Publication Number Publication Date
EP1616182A2 EP1616182A2 (en) 2006-01-18
EP1616182A4 true EP1616182A4 (en) 2008-04-16

Family

ID=33030003

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04757538A Withdrawn EP1616182A4 (en) 2003-03-18 2004-03-17 Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2

Country Status (2)

Country Link
EP (1) EP1616182A4 (en)
WO (1) WO2004082627A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076102B2 (en) * 2005-05-18 2011-12-13 Biofactura, Inc. Compositions and methods for metabolic selection of transfected cells
WO2011006510A1 (en) 2009-07-17 2011-01-20 Technical University Of Denmark Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
JP5947807B2 (en) 2010-12-14 2016-07-06 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ Encapsulation of radionuclides in nanoparticle compositions
DE102012002929A1 (en) * 2012-02-14 2013-08-14 Jürgen Lewald Analyzing a peripheral blood sample of a female subject based on concentration of a steroid hormone that indicates endometriosis, comprising e.g. testosterone, progesterone, cortisol, dehydroepiandrosterone and androstenedione
CN113280980B (en) * 2021-04-27 2022-07-01 中国原子能科学研究院 Target detection method and device

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULUN S E ET AL: "Mechanisms of excessive estrogen formation in endometriosis", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, ELSEVIER SCIENCE IRELAND LTD, IE, vol. 55, 2002, pages 21 - 33, XP002983135, ISSN: 0165-0378 *
KITAWAKI J ET AL: "Endometriosis: The pathophysiology as an estrogen-dependent disease.", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 83, no. 1-5, December 2002 (2002-12-01), pages 149 - 155, XP002470931, ISSN: 0960-0760 *
UTSUNOMIYA HIROKI ET AL: "The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, ENDOCRINE SOCIETY, CHEVY CHASE, MD, US, vol. 86, no. 7, July 2001 (2001-07-01), pages 3436 - 3443, XP009096560, ISSN: 0021-972X *
ZEITOUN KM ET AL: "Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target", FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, US, vol. 72, no. 6, December 1999 (1999-12-01), pages 961 - 969, XP002211657, ISSN: 0015-0282 *

Also Published As

Publication number Publication date
EP1616182A2 (en) 2006-01-18
WO2004082627A2 (en) 2004-09-30
WO2004082627A3 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
HU0302451D0 (en) New compounds with therapeutic effect
GB2405115B (en) Hole-saw assembly including two hole-saws
TWI319007B (en) Subtilase variants
GB2387387B (en) Stabilizer mixtures
GB0309138D0 (en) Design 2
GB0312517D0 (en) Embroidered electrode
AU2003274975A8 (en) Electrooptic assembly
AU2003238930A8 (en) Enzymes
EP1490074A4 (en) Mixed- cell gene therapy
AU2003275501A8 (en) Drive arrangement
GB0327384D0 (en) Gene therapy
EP1616182A4 (en) Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2
GB2389535B (en) Incubator
EP1552839A4 (en) Separate type medical material
EP1614746A4 (en) Fructosylamine oxidase
AU2003245747A8 (en) Enzymes
GB0327907D0 (en) Microorganism
AU2003294705A8 (en) Ntsm gene
GB2387883B (en) Drive arrangement
GB0213745D0 (en) Enzyme
AU2003220607A8 (en) Enzymes
GB0309136D0 (en) Design 1
HRP20020648A2 (en) Racket-raster matrix
GB0310457D0 (en) Enzyme
EP1514924A4 (en) Novel acylase gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051018

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 5/24 20060101ALI20080306BHEP

Ipc: G01N 33/53 20060101AFI20050330BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080317

17Q First examination report despatched

Effective date: 20090327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090807